logo-loader
viewLexaria Bioscience Corp.

Lexaria Bio Science signs 5-year deal to provide technology to Universal Hemp

Lexaria Bioscience Corp (CSE:LXX) Chairman and CEO Chris Bunka joined Steve Darling from Proactive Investors Vancouver on Skype to bring news the company has agreed to a 5-year deal that will allow Universal Hemp to use their DehydraTECH technology.

This deal will work under a royalty agreement but terms of that part of the deal are not being disclosed, but the deal is worth a min 3.75 million US.

 

Quick facts: Lexaria Bioscience Corp.

Price: 0.37 CAD

CSE:LXX
Market: CSE
Market Cap: $33.15 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Lexaria Bio Science files patent for technology to treat...

Lexaria Bioscience (CSE: LXX-OTC: LXRP) CEO Chris Bunka joined Steve Darling from Proactive Vancouver to discuss the company has filed a patent for their DehydraTech technology for the delivery of antiviral drugs. Bunka telling Proactive this technology would potentially be used to improve...

on 21/4/20

2 min read